Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System

Michele Fusaroli; Stefano Polizzi; Luca Menestrina; Valentina Giunchi; Luca Pellegrini; Emanuel Raschi; Daniel Weintraub; Maurizio Recanatini; Gastone Castellani; Fabrizio De Ponti; Elisabetta Poluzzi

doi:10.1007/s40264-024-01471-z

Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System

Michele Fusaroli
, Stefano Polizzi
, Luca Menestrina
, Valentina Giunchi
, Luca Pellegrini
, Emanuel Raschi
, Daniel Weintraub
, Maurizio Recanatini
, Gastone Castellani
, Fabrizio De Ponti
, Elisabetta Poluzzi

Department of Psychology, Sport and Geography

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

12 Downloads (Pure)

Abstract

Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.

Original language	English
Number of pages	18
Journal	Drug Safety
Early online date	15 Aug 2024
DOIs	https://doi.org/10.1007/s40264-024-01471-z
Publication status	E-pub ahead of print - 15 Aug 2024

Access to Document

10.1007/s40264-024-01471-zLicence: CC BY-NC

Final_Version
© 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC), https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 2.11 MBLicence: CC BY-NC

Cite this

@article{31fc00372b684b52bd18c9812cf08bf9,

title = "Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System",

abstract = "Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.",

author = "Michele Fusaroli and Stefano Polizzi and Luca Menestrina and Valentina Giunchi and Luca Pellegrini and Emanuel Raschi and Daniel Weintraub and Maurizio Recanatini and Gastone Castellani and \{De Ponti\}, Fabrizio and Elisabetta Poluzzi",

note = "{\textcopyright} 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC), https://creativecommons.org/licenses/by-nc/4.0/ ",

year = "2024",

month = aug,

day = "15",

doi = "10.1007/s40264-024-01471-z",

language = "English",

journal = "Drug Safety",

issn = "1179-1942",

publisher = "Adis",

}

TY - JOUR

T1 - Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System

AU - Fusaroli, Michele

AU - Polizzi, Stefano

AU - Menestrina, Luca

AU - Giunchi, Valentina

AU - Pellegrini, Luca

AU - Raschi, Emanuel

AU - Weintraub, Daniel

AU - Recanatini, Maurizio

AU - Castellani, Gastone

AU - De Ponti, Fabrizio

AU - Poluzzi, Elisabetta

N1 - © 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC), https://creativecommons.org/licenses/by-nc/4.0/

PY - 2024/8/15

Y1 - 2024/8/15

N2 - Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.

AB - Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.

U2 - 10.1007/s40264-024-01471-z

DO - 10.1007/s40264-024-01471-z

M3 - Article

SN - 1179-1942

JO - Drug Safety

JF - Drug Safety

ER -

Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System

Abstract

Access to Document

Fingerprint

Cite this